Tempus Announces Strategic Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Clinical Differentiation Across an ADC Clinical Program

AI Briefing

• – Tempus and Daiichi Sankyo to accelerate ADC clinical development and differentiation in oncology through AI-driven biomarker discovery.
• – Tempus' PRISM2 foundation model to be leveraged by Daiichi Sankyo for ADC program.
• – Collaboration aims to bring innovative ADC therapies to patients with cancer more quickly and effectively.